Abstract
Sepsis and its sequelae are the leading causes of death among critically ill patients in non-coronary intensive care units (ICUs). Paradoxically, despite a fall in the mortality rate, the incidence of sepsis has increased, with about 750,000 cases annually resulting in about 215,000 deaths a year [1, 2]. This is, in part, a consequence of increased provision of intensive care facilities in the UK and elsewhere [3]. Many factors contribute to the increasing incidence of sepsis and its sequelae including improved chemotherapy for malignancies leading to greater numbers of immunosuppressed patients; more organ transplantations and cardiac surgery; and also the increased use of internal devices such as prostheses, chest drains and endotracheal tubes [3]. Moreover, 40–60% of patients with severe sepsis develop acute lung injury (ALI) or its extreme manifestation, acute respiratory distress syndrome (ARDS), which is associated with a particularly high mortality [4, 5].
Keywords
- Severe Sepsis
- Acute Lung Injury
- Systemic Inflammatory Response Syndrome
- Invasive Pneumococcal Disease
- Drotrecogin Alfa
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1309
Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time. Crit Care Med 26:2078–2086
Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC (2005) Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 33:1191–1198
MacCallum NS, Evans TW (2005) Epidemiology of acute lung injury. Curr Opin Crit Care 11:43–49
Brun-Buisson C, Doyon F, Carlet J (1996) Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 154:617–624
Geerdes HF, Ziegler D, Lode H, et al (1992) Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 15:991–1002
Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann C (2003) Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 20:402–414
Detmer K, Wang Z, Warejcka D, Leeper-Woodford SK, Newman WH (2001) Endotoxin stimulated cytokine production in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 281:H661–H668
Martich GD, Boujoukos AJ, Suffredini AF (1993) Response of man to endotoxin. Immunobiology 187:403–416
Parker SJ, Watkins PE (2001) Experimental models of gram-negative sepsis. Br J Surg 88: 22–30
Fischer W, Mannsfeld T, Hagen G (1990) On the basic structure of poly(glycerophosphate) lipoteichoic acids. Biochem Cell Biol 68:33–43
Ginsburg I (2002) The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 110:753–770
Lemaitre B, Reichhart JM, Hoffmann JA (1997) Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci USA 94:14614–14619
O’Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3:396–403
O’Neill LA, Fitzgerald KA, Bowie AG (2003) The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 24:286–290
O’Neill LA (2006) How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 18:3–9
Poltorak A, He X, Smirnova I, et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/ l0ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088
Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680
Yamamoto M, Sato S, Mori K et al (2002) Cutting edge: a novel Toll/IL-1 receptor domaincontaining adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169:6668–6672
Yamamoto M, Sato S, Hemmi H, et al (2003) TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4:1144–1150
Takeuchi O, Hoshino K, Akira S (2000) Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165:5392–5396
Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, Landmann R (2002) Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 186:798–806
Lien E, Sellati TJ, Yoshimura A, et al (1999) Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 274:33419–33425
Takeuchi O, Kawai T, Muhlradt PF, et al (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13:933–940
Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565–575
Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181:176–180
Fisher CJ, Jr., Opal SM, Dhainaut JF, et al (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21:318–327
Bjerre A, Brusletto B, Hoiby EA, Kierulf P, Brandtzaeg P (2004) Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32:433–438
Re F, Strominger JL (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276:37692–37699
Fisher CJ Jr., Agosti JM, Opal SM, et al (1996) Treatment of septic shock with the tumor necrosis factor recepton:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697–1702
Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24:1431–1440
Dhainaut JF, Tenaillon A, Le Tulzo Y, et al (1994) Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 22:1720–1728
Fisher CJ Jr, Dhainaut JF, Opal SM, et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836–1843
The French National Registry of HA-1A (Centoxin) in septic shock (1994) A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 154: 2484–2491
Fein AM, Bernard GR, Criner GJ, et al (1997) Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277:482–487
Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Opal SM, Garber GE, LaRosa SP, et al (2003) Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 37:50–58
American College of Chest Physicians/Society of Critical Care Medicine (1992) Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874
Vincent JL (1997) Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 25:372–374
Levy MM, Fink MP, Marshall JC, et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538
Peters RP, van Agtmael MA, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, Savelkoul PH (2006) Rapid identification of pathogens in blood cultures with a modified fluorescence in situ hybridization assay. J Clin Microbiol 44:4186–4188
Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med 32:1706–1712
Arbour NC, Lorenz E, Schutte BC, et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187–191
Kiechl S, Lorenz E, Reindl M, et al (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185–192
Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA (2000) A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68:6398–6401
Khor CC, Chapman SJ, Vannberg FO, et al (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39:523–528
Meng G, Rutz M, Schiemann M, et al (2004) Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 113:1473–1481
Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ (1998) Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 95:13875–13880
Reinhart K, Gluck T, Ligtenberg J, et al (2004) CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 32:1100–1108
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media Inc.
About this paper
Cite this paper
Leaver, S., Burke Gaffney, A., Evans, T.W. (2008). Gram-positive and Gram-negative Sepsis: Two Disease Entities?. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77383-4_37
Download citation
DOI: https://doi.org/10.1007/978-0-387-77383-4_37
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77382-7
Online ISBN: 978-0-387-77383-4
eBook Packages: MedicineMedicine (R0)